Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis.

Sheng, Guangying

Societal implications of medical insurance coverage for imatinib as first-line treatment of chronic myeloid leukemia in China: a cost-effectiveness analysis. [electronic resource] - Journal of medical economics Apr 2017 - 371-381 p. digital

Publication Type: Journal Article

1941-837X

10.1080/13696998.2016.1271336 doi


Antineoplastic Agents--administration & dosage
China
Cost-Benefit Analysis
Decision Support Techniques
Humans
Imatinib Mesylate--administration & dosage
Insurance Coverage--economics
Insurance, Health--economics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Markov Chains
Pyrimidines--administration & dosage
Quality-Adjusted Life Years